title: Progesterone, 17 beta-estradiol, and opioid neuropeptides modulate pattern of luteinizing hormone in circulation of the cow.
abstract: The working hypothesis for this study was that 17 beta-estradiol (E2), progesterone (P4), and opioid neuropeptides modulate frequency of pulsatile release of LH during the luteal phase of the bovine estrous cycle. On Day 8 of the estrous cycle (Day 0 = estrus), 20 cows were ovariectomized (OVX) and immediately received one of three steroid replacement treatments: P4 alone (n = 6), E2 alone (n = 7), or P4 and E2 (n = 7). To characterize the pattern of LH in peripheral circulation, serial blood samples were collected (12-min intervals for 22 h) on the fifth day following OVX. LHRH was administered after the 22-h sample was taken. Naloxone (opioid neuropeptide antagonist; 0.5 mg/kg) was administered on the sixth day after OVX, and change of concentration of LH in peripheral circulation was monitored. Pulse frequency of LH and mean concentration of LH were lower (p < 0.01) in cows treated with P4 and E2 compared to cows treated with P4 alone. Moreover, cows treated with E2 alone had a greater (p < 0.01) frequency of LH pulses and mean concentration of LH compared to cows treated with P4 alone. The greatest amplitude (p < 0.01) of LH release after LHRH was in cows treated with E2 alone. The greatest percentage increase (p < 0.01) in LH after administration of naloxone occurred in cows treated with P4 alone.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Animal Science, University of Nebraska, Lincoln 68583-0908.
authors.forename: T T
authors.initials: TT
authors.lastname: Stumpf
authors.forename: M S
authors.initials: MS
authors.lastname: Roberson
authors.forename: M W
authors.initials: MW
authors.lastname: Wolfe
authors.forename: D L
authors.initials: DL
authors.lastname: Hamernik
authors.forename: R J
authors.initials: RJ
authors.lastname: Kittok
authors.forename: J E
authors.initials: JE
authors.lastname: Kinder
mesh_terms: D000818:Animals; D002417:Cattle; D004347:Drug Interactions; D004723:Endorphins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000494:pharmacology; D008183:Luteal Phase / Q000187:drug effects / Q000502:physiology; D007986:Luteinizing Hormone / Q000097:blood* / Q000378:metabolism; D009270:Naloxone / Q000494:pharmacology; D010052:Ovariectomy; D010053:Ovary / Q000502:physiology; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism; D011374:Progesterone / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D004723:Endorphins; D007987:Gonadotropin-Releasing Hormone; D009270:Naloxone; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone